- Home
- OPCH vs HAE Comparison
OPCH vs HAE Comparison
Compare OPCH & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | HAE |
|---|---|---|
| Founded | N/A | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.8B |
| IPO Year | 1996 | 1996 |
Fundamental Metrics
Financial Performance| Metric | OPCH | HAE |
|---|---|---|
| Price | $21.66 | $75.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $36.57 | ★ $84.13 |
| AVG Volume (30 Days) | ★ 2.9M | 1.0M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.25 | N/A |
| EPS | 0.29 | ★ 2.05 |
| Revenue | ★ $4,998,202,000.00 | $910,373,000.00 |
| Revenue This Year | $7.21 | N/A |
| Revenue Next Year | $8.55 | $5.23 |
| P/E Ratio | $73.66 | ★ $36.60 |
| Revenue Growth | ★ 16.17 | N/A |
| 52 Week Low | $18.01 | $47.32 |
| 52 Week High | $36.80 | $87.32 |
Technical Indicators
Market Signals| Indicator | OPCH | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 58.46 |
| Support Level | $19.61 | $72.04 |
| Resistance Level | $22.42 | $80.90 |
| Average True Range (ATR) | 0.70 | 2.91 |
| MACD | 0.08 | -0.58 |
| Stochastic Oscillator | 45.71 | 38.17 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.